Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.

Citation data:

Nucleic acids research, ISSN: 1362-4962, Vol: 44, Issue: 7, Page: 3304-16

Publication Year:
Usage 5
Abstract Views 4
Link-outs 1
Captures 16
Readers 16
Social Media 2
Tweets 2
Citations 2
Citation Indexes 2
Malik, Muhammad, Mustaev, Arkady, Schwanz, Heidi A., Luan, Gan, Shah, Nirali, Oppegard, Lisa M., de Souza, Ernane C., Hiasa, Hiroshi, Zhao, Xilin, Kerns, Robert J., Drlica, Karl Show More Hide
Oxford University Press (OUP)
Biochemistry, Genetics and Molecular Biology
Most Recent Tweet View All Tweets
article description
Fluoroquinolones form drug-topoisomerase-DNA complexes that rapidly block transcription and replication. Crystallographic and biochemical studies show that quinolone binding involves a water/metal-ion bridge between the quinolone C3-C4 keto-acid and amino acids in helix-4 of the target proteins, GyrA (gyrase) and ParC (topoisomerase IV). A recent cross-linking study revealed a second drug-binding mode in which the other end of the quinolone, the C7 ring system, interacts with GyrA. We report that addition of a dinitrophenyl (DNP) moiety to the C7 end of ciprofloxacin (Cip-DNP) reduced protection due to resistance substitutions in Escherichia coli GyrA helix-4, consistent with the existence of a second drug-binding mode not evident in X-ray structures of drug-topoisomerase-DNA complexes. Several other C7 aryl fluoroquinolones behaved in a similar manner with particular GyrA mutants. Treatment of E. coli cultures with Cip-DNP selectively enriched an uncommon variant, GyrA-A119E, a change that may impede binding of the dinitrophenyl group at or near the GyrA-GyrA interface. Collectively the data support the existence of a secondary quinolone-binding mode in which the quinolone C7 ring system interacts with GyrA; the data also identify C7 aryl derivatives as a new way to obtain fluoroquinolones that overcome existing GyrA-mediated quinolone resistance.

This article has 0 Wikipedia reference.